NCT06114745View on ClinicalTrials.gov

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

July 8, 2025

Study Completion Date

July 8, 2025

Conditions
Alzheimer's Disease (AD)
Interventions
DRUG

SHR-1707 injection

Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion

DRUG

Placebo

Placebo will be administered through IV infusion

Trial Locations (3)

Unknown

Liverpool Hospital, Sydney

Southern Neurology, Sydney

Austin Health, Melbourne

All Listed Sponsors
lead

Atridia Pty Ltd.

INDUSTRY

NCT06114745 - A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease | Biotech Hunter | Biotech Hunter